Drug Eluting Stents
10.5K views | +2 today
Follow
Drug Eluting Stents
Your new post is loading...
Your new post is loading...
Scooped by Beeyond
Scoop.it!

TCT: Studies Suggest Thin May not Always be In for DES

TCT: Studies Suggest Thin May not Always be In for DES | Drug Eluting Stents | Scoop.it
Challengers to the Orsiro stent met their non-inferiority goals and forced the question: are thinner struts really better in drug-eluting stent technology?
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy

Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy | Drug Eluting Stents | Scoop.it
Several sources of utility decrements for bleeds are available for use in cost-effectiveness analyses, but are of limited quality and relevance. Our elicitation exercise has derived utility decrements from a relevant patient population, based on standardised definitions of minor and major bleeding events, using a validated HRQoL instrument and have been valued using general population tariffs. We suggest that our utility decrements be used in future cost-effectiveness analyses of DAPT.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Multi-scale simulations of the dynamics of in-stent restenosis: impact of stent deployment and design

The development of the simulated restenosis as a function of stent deployment depth is compared with an in vivo porcine dataset. Moreover, the influence of strut size and shape is investigated, and the effect of a drug released at the site of injury, by means of a drug-eluting stent, is also examined. A strong correlation between strut thickness and the rate of smooth muscle cell proliferation has been observed. Simulation results also suggest that the growth of the restenotic lesion is strongly dependent on the stent strut cross-sectional profile.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

A New Drug And Delivery Platform As An Alternative To Stent Placement Surgery

A New Drug And Delivery Platform As An Alternative To Stent Placement Surgery | Drug Eluting Stents | Scoop.it

Cardiovascular disease remains the number one reason for mortality and morbidity in the US, particularly given the ever-increasing prevalence of metabolic syndromes like diabetes and obesity. When a vasculature is occluded or stenotic, insufficient blood supply will lead to ischemia, followed by grave consequences like a heart attack or stroke. To restore the patency of the clogged vasculature, vascular surgeons and cardiologists have long been resorting to surgical intervention strategies such as open bypass surgeries and endovascular procedures.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Drug Eluting Stents: Arsenic Trioxide–Coated Stent Is an Endothelium‐Friendly Drug Eluting Stent

Drug Eluting Stents: Arsenic Trioxide–Coated Stent Is an Endothelium‐Friendly Drug Eluting Stent | Drug Eluting Stents | Scoop.it

Traditional drug‐eluting stents often delay endothelialization whilst inhibiting intimal hyperplasia. In article 1800207 by Juhui Qiu, Guixue Wang, and co‐workers, an arsenic trioxide‐eluting stent effectively facilitates rapid re‐endothelialization whilst preventing in‐stent restenosis. 

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST

A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST | Drug Eluting Stents | Scoop.it
The BIOSTEMI trial will determine whether ultrathin-strut BP-SES are superior to thin-strut DP-EES with respect to TLF in patients with STEMI undergoing PPCI.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients | Drug Eluting Stents | Scoop.it

The study was small, short, and used a surrogate endpoint, but one expert posits that future bioresorbable scaffolds may have a niche in STEMI.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Balloons as effective as stents to open small arteries, study says

Balloons as effective as stents to open small arteries, study says | Drug Eluting Stents | Scoop.it
Drug-coated balloons worked just as well as stents for clearing blockages in small arteries that were clogged for the first time, sparing patients the need for a permanent implant, according to a new study presented at the European Society of Cardiology Congress in Munich and published in the Lancet.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Short DAPT with Ticagrelor Doesn't Improve Outcomes

Short DAPT with Ticagrelor Doesn't Improve Outcomes | Drug Eluting Stents | Scoop.it
Antiplatelet strategy safe, but misses superiority to standard DAPT after stenting
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the coronary bifurcation stenting registry II

Benefit of prolonged dual antiplatelet therapy after implantation of drug-eluting stent for coronary bifurcation lesions: results from the coronary bifurcation stenting registry II | Drug Eluting Stents | Scoop.it

Although it seems that a default strategy of ≥12 months DAPT for all contemporary bifurcation PCI could hardly be advocated based on the presented results, the observed favorable outcomes with prolonged antiplatelet treatment may warrant further research toward identification of patients who may benefit from long DAPT after having undergone bifurcation stenting.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Cover Art–Drug‐Eluting Stents, Flexible Sensors & Bioimaging

Cover Art–Drug‐Eluting Stents, Flexible Sensors & Bioimaging | Drug Eluting Stents | Scoop.it

Traditional drug‐eluting stents often delay endothelialization whilst inhibiting intimal hyperplasia. In their article, Juhui Qiu, Guixue Wang, and co‐workers describe an arsenic trioxide‐elutin g stent that  effectively facilitates rapid re‐endothelialization whilst preventing in‐stent restenosis.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

The outperformance of the ultrathin, bioresorbable polymer sirolimus-eluting stent over the durable polymer everolimus-eluting stent in a complex patient population undergoing percutaneous coronary intervention suggests a new direction in improving next generation drug-eluting stent technology.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Microsoft, Samsung, And Other Nontraditional Healthcare Players Pursuing Cardiovascular Device Innovation

Microsoft, Samsung, And Other Nontraditional Healthcare Players Pursuing Cardiovascular Device Innovation | Drug Eluting Stents | Scoop.it
As the medical device market reinvents itself through digital innovation, more nontraditional players — such as hardware companies — are entering the space and developing new solutions.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Metanalysis of the Impact of Strut Thickness on Outcomes in Patients with Drug-Eluting Stents in a Coronary Artery

Metanalysis of the Impact of Strut Thickness on Outcomes in Patients with Drug-Eluting Stents in a Coronary Artery | Drug Eluting Stents | Scoop.it
The aim of this network metanalysis is to assess the impact of strut thickness on clinical outcomes in patients undergoing percutaneous coronary intervention (PCI). We searched Medline/PubMed and performed a Bayesian network meta-analysis to compare outcomes of patients undergoing PCI with DES of different strut thicknesses (ultrathin 60-80 μm; thin 81-100 μm; intermediate 101-120 μm; thick ≥120 μm).
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

FDA approves first rescue stent to seal coronary artery tears in 17 years

FDA approves first rescue stent to seal coronary artery tears in 17 years | Drug Eluting Stents | Scoop.it

Deep tears in coronary arteries can occur on rare occasions during percutaneous interventions, where stents are inserted via a catheter to expand narrowed vessels to increase blood flow to the heart.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Recognition for drug-eluting stent that unclogs vessels

Recognition for drug-eluting stent that unclogs vessels | Drug Eluting Stents | Scoop.it

Patients expect to save money thanks to precise delivery of drug thanks to Chinese invention.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View

Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View | Drug Eluting Stents | Scoop.it
The technology of percutaneous coronary intervention (PCI) is constantly being refined in order to overcome the shortcomings of present day technologies. Even though current generation metallic drug-eluting stents (DES) perform very well in the short-term, concerns still exist about their long-term efficacy. Late clinical complications including late stent thrombosis (ST), restenosis, and neoatherosclerosis still exist and many of these events may be attributed to either the metallic platform and/or the drug and polymer left behind in the arterial wall. To overcome this limitation, the concept of totally bioresorbable vascular scaffolds (BRS) was invented with the idea that by eliminating long-term exposure of the vessel wall to the metal backbone, drug, and polymer, late outcomes would improve.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Long-Term Antiplatelet Monotherapy After Stenting Is Safe, But Does Not Improve Outcomes

Long-Term Antiplatelet Monotherapy After Stenting Is Safe, But Does Not Improve Outcomes | Drug Eluting Stents | Scoop.it

Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented in a Hot Line Session at ESC Congress 2018 and published in The Lancet.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Higher all-cause mortality with Orsiro at five years than with Xience

Higher all-cause mortality with Orsiro at five years than with Xience | Drug Eluting Stents | Scoop.it

According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biodegradable polymer (Orsiro, Biotronik) have a similar overall safety and efficacy profile as everolimus-eluting stents (Xience, Abbott). However, the study also found that all-cause mortality was significantly higher in patients receiving Orsiro and this higher rate was driven by a higher rate of non-cardiovascular deaths (mainly cancer).

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Small vessels could make a big difference to B Braun

Small vessels could make a big difference to B Braun | Drug Eluting Stents | Scoop.it

Data showing that SeQuent Please, the paclitaxel-coated balloon sold by B Braun, is non-inferior to drug-eluting stents in the treatment of small blocked blood vessels ought to boost sales of the device, the company says.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Double robust estimation for multiple unordered treatments and clustered observations: Evaluating drug‐eluting coronary artery stents

Double robust estimation for multiple unordered treatments and clustered observations: Evaluating drug‐eluting coronary artery stents | Drug Eluting Stents | Scoop.it
The Massachusetts Data Analysis Center percutaneous coronary intervention cohort is used to assess the composite outcome of 10 drug‐eluting stents among adults implanted with at least one drug‐eluting stent in Massachusetts. We find remarkable discrimination between stents. A simulation study designed to mimic this coronary intervention cohort is also presented and produced similar results.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Long-term antiplatelet monotherapy after stenting is safe but does not improve outcomes

Long-term antiplatelet monotherapy after stenting is safe but does not improve outcomes | Drug Eluting Stents | Scoop.it
Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented today in a Hot Line Session at ESC Congress 20181 and published in The Lancet.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Dual Antiplatelet Therapy Cessation and Adverse Events after Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis

Dual Antiplatelet Therapy Cessation and Adverse Events after Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis | Drug Eluting Stents | Scoop.it
The degree of atherothrombotic risk influences the pattern and mode of DAPT cessation with less discontinuation among patients considered HATR. ATR status does not influence the association between DAPT cessation and cardiac risk.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease

Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease | Drug Eluting Stents | Scoop.it
CABG had a mortality benefit over PCI in patients with multivessel disease, particularly those with diabetes and higher coronary complexity. No benefit for CABG over PCI was seen in patients with left main disease. Longer follow-up is needed to better define mortality differences between the revascularisation strategies.
more...
No comment yet.